Literature DB >> 3042080

Ileocolonoscopic findings in seronegative spondylarthropathies.

H Mielants, E M Veys, C Cuvelier, M de Vos.   

Abstract

Ileocolonoscopy with biopsy of caecum, ileocaecal valve and terminal ileum were performed on 232 patients with seronegative spondylarthropathies and on 65 control patients. Inflammatory gut lesions were found in 65% of the patients with reactive arthritis (ReA) and in 57% of the patients with ankylosing spondylitis (AS), especially in those with peripheral arthritis. The controls had a normal gut. This finding would suggest that exogenous factors causing inflammation of the gut lead to a disturbed permeability of the gut wall or to a deficient local immunological defence mechanism permitting antigens to enter the circulation, inducing the joint and tendon inflammation. Support for this hypothesis was provided by the results of a repeat ileocolonoscopy, disclosing a strong association between the presence of gut inflammation on biopsy and the persistence of joint inflammation. Patients presenting some of the histological lesions found on biopsy (especially active chronic lesions) and patients with proven Crohn's disease were found to share a genetic marker (HLA-BW62). This would suggest that some of the patients with seronegative spondylarthropathies suffer from a subclinical form of Crohn's disease of which the joint symptoms are the unique clinical manifestation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3042080     DOI: 10.1093/rheumatology/xxvii.suppl_2.95

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  60 in total

Review 1.  Treatment of active spondyloarthropathy with infliximab, the chimeric monoclonal antibody to tumour necrosis factor alpha.

Authors:  F Van den Bosch; D Baeten; E Kruithof; F De Keyser; H Mielants; E M Veys
Journal:  Ann Rheum Dis       Date:  2001-11       Impact factor: 19.103

2.  Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study.

Authors:  F Van den Bosch; E Kruithof; D Baeten; F De Keyser; H Mielants; E M Veys
Journal:  Ann Rheum Dis       Date:  2000-06       Impact factor: 19.103

3.  Increased intestinal permeability in ankylosing spondylitis.

Authors:  H Mielants; E M Veys; M De Vos; C Cuvelier
Journal:  Gut       Date:  1992-08       Impact factor: 23.059

4.  Anti-saccharomyces cerevisiae IgA antibodies are raised in ankylosing spondylitis and undifferentiated spondyloarthropathy.

Authors:  I E A Hoffman; P Demetter; M Peeters; M De Vos; H Mielants; E M Veys; F De Keyser
Journal:  Ann Rheum Dis       Date:  2003-05       Impact factor: 19.103

Review 5.  Small intestinal mucosal protection mechanisms and their importance in rheumatology.

Authors:  S O'Mahony; A Ferguson
Journal:  Ann Rheum Dis       Date:  1991-05       Impact factor: 19.103

Review 6.  The microbiome, HLA, and the pathogenesis of uveitis.

Authors:  James T Rosenbaum; Phoebe Lin; Mark Asquith
Journal:  Jpn J Ophthalmol       Date:  2015-09-14       Impact factor: 2.447

7.  Subclinical gut inflammation in spondyloarthropathy patients is associated with upregulation of the E-cadherin/catenin complex.

Authors:  P Demetter; D Baeten; F De Keyser; M De Vos; N Van Damme; G Verbruggen; S Vermeulen; M Mareel; D Elewaut; H Mielants; E M Veys; C A Cuvelier
Journal:  Ann Rheum Dis       Date:  2000-03       Impact factor: 19.103

Review 8.  The treatment of the rheumatological manifestations of the inflammatory bowel diseases.

Authors:  Melissa Padovan; Gabriella Castellino; Marcello Govoni; Francesco Trotta
Journal:  Rheumatol Int       Date:  2006-06-24       Impact factor: 2.631

9.  Clinically silent inflammatory gut lesions in undifferentiated spondyloarthropathies.

Authors:  L Altomonte; A Zoli; A Veneziani; L Mirone; G Santacesaria; C Chiarelli; F Federico; G Massi; M Magaro
Journal:  Clin Rheumatol       Date:  1994-12       Impact factor: 2.980

10.  Comorbidities in Argentine patients with axial spondyloarthritis: Is nephrolithiasis associated with this disease?

Authors:  Fernando Sommerfleck; Emilce Schneeberger; Gustavo Citera
Journal:  Eur J Rheumatol       Date:  2018-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.